Arcadia Biosciences Q4 revenue +56% YoY to $1.2M; net loss widens; Roosevelt deal on track

Arcadia Biosciences, Inc.

Q4 total revenues $1.216M (+56% YoY); FY2024 revenues $5.045M (+13% YoY).
Net loss attributable to common stockholders Q4 $4.064M ($2.98/share) vs $2.853M in Q4 2023.
Full-year net loss improved to $7.038M ($3.17/share) from $13.981M in 2023.
Zola coconut water revenue up 124% in Q4 and 46% for full year.
Pending merger with Roosevelt Resources; post-close owners get ~90% of shares, Arcadia holders ~10%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.